
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule containing hydrocodone bitartrate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved. Hydrocodone is a Schedule II controlled substance.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing hydrocodone are listed in capsule, tablet, solution, suspension, liquid and syrup forms.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Hydrocodone is a Schedule II opioid pain reliever that compounding pharmacies prepare by prescription in several dosage forms.
Hydrocodone is a semisynthetic opioid that acts mainly as a full agonist at mu-opioid receptors, changing how the brain and nervous system respond to pain; like other full agonists it has no ceiling effect for pain relief. Single-ingredient extended-release products, such as Hysingla ER tablets and hydrocodone bitartrate extended-release capsules, are FDA-approved for severe and persistent pain that requires an opioid and cannot be adequately treated with alternatives, including immediate-release opioids, and are not for as-needed use. Hydrocodone is also manufactured in combination with acetaminophen and in cough combination products. A prescriber might order hydrocodone compounded when a patient needs a strength or dosage form that is not manufactured. Compounded preparations are not FDA-approved and require a prescription. Hydrocodone is a federally controlled Schedule II substance.
Hysingla ER carries a boxed warning covering addiction, abuse and misuse; life-threatening breathing problems, especially when starting or after a dose increase; the need to swallow tablets whole; fatal accidental ingestion, especially by children; profound sedation, coma or death with benzodiazepines, alcohol or other CNS depressants; neonatal opioid withdrawal syndrome; the opioid REMS program; and interactions with CYP3A4 inhibitors and inducers. Do not use it with significant breathing problems, acute or severe asthma without monitoring, or known or suspected bowel blockage, or if you are allergic to hydrocodone. Other warnings include adrenal insufficiency, severe low blood pressure, QT prolongation, seizures, opioid-induced hyperalgesia, withdrawal and impaired driving. Long-term use in pregnancy can cause withdrawal in the newborn. The label says breastfeeding is not recommended, and LactMed notes newborns are especially sensitive to opioid sedation. Talk to your prescriber or pharmacist about side effects.
Hydrocodone is a full mu-opioid agonist; StatPearls notes delta and kappa receptor activation as plasma concentrations rise. Per the Hysingla ER label, plasma protein binding is about 36%; CYP3A4-mediated N-demethylation to inactive norhydrocodone is the primary pathway, with minor contributions from CYP2B6 and CYP2C19, while CYP2D6 forms hydromorphone, a minor active metabolite (under 3% of circulating parent). Hysingla ER reaches median Tmax at 14 to 16 hours with a mean terminal half-life of 7 to 9 hours; StatPearls gives about 4 hours for immediate-release hydrocodone and notes mainly renal excretion. Labeled indication: severe and persistent pain requiring an opioid analgesic when alternatives, including immediate-release opioids, are inadequate; not an as-needed analgesic. StatPearls notes the FDA restricted prescription hydrocodone cough and cold products to adults 18 and older in 2018. Dosing is per prescriber. Monitor respiratory status, sedation, misuse, bowel function and changes in CYP3A4 inhibitors or inducers. Hydrocodone is Schedule II. Electronic prescribing of controlled substances is voluntary under federal DEA rules, CMS applies a prescriber-level threshold for Part D, and a number of states mandate it.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth